A Longitudinal Study Comparing SF2/ASF Modulation in Multiple Sclerosis (MS) Patients Treated with Natalizumab and Fingolimod and Healthy Volunteers
Latest Information Update: 20 Feb 2018
At a glance
- Drugs Natalizumab (Primary) ; Fingolimod
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics
- 20 Feb 2018 New trial record